Janus Henderson Group
MRNA icon

Janus Henderson Group’s Moderna MRNA Stock Holding History

Janus Henderson Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.1M Buy
159,372
+6,337
+4% +$296K ﹤0.01% 826
2025
Q4 		$4.51M Sell
153,035
-14,076
-8% -$382K ﹤0.01% 977
2025
Q3 		$4.31M Buy
167,111
+2,362
+1% +$65.9K ﹤0.01% 967
2025
Q2 		$4.54M Buy
164,749
+125,521
+320% +$3.31M ﹤0.01% 934
2025
Q1 		$1.22M Buy
39,228
+1,545
+4% +$54.8K ﹤0.01% 1525
2024
Q4 		$1.57M Sell
37,683
-2,924
-7% -$140K ﹤0.01% 1441
2024
Q3 		$2.71M Buy
40,607
+3,700
+10% +$340K ﹤0.01% 1157
2024
Q2 		$4.38M Sell
36,907
-8,519
-19% -$1.08M ﹤0.01% 897
2024
Q1 		$4.84M Sell
45,426
-107
-0.2% -$10.8K ﹤0.01% 891
2023
Q4 		$4.53M Sell
45,533
-386,480
-89% -$32.5M ﹤0.01% 851
2023
Q3 		$44.6M Buy
432,013
+40,295
+10% +$4.49M 0.03% 384
2023
Q2 		$47.6M Buy
391,718
+338,671
+638% +$45.2M 0.03% 398
2023
Q1 		$8.15M Buy
53,047
+9,252
+21% +$1.53M 0.01% 745
2022
Q4 		$7.86M Sell
43,795
-211,549
-83% -$34.6M 0.01% 770
2022
Q3 		$30.2M Sell
255,344
-22,792
-8% -$3.46M 0.02% 474
2022
Q2 		$39.7M Sell
278,136
-400,978
-59% -$57.3M 0.03% 428
2022
Q1 		$117M Sell
679,114
-159,081
-19% -$26.8M 0.06% 292
2021
Q4 		$213M Buy
838,195
+167,352
+25% +$48.9M 0.09% 223
2021
Q3 		$258M Sell
670,843
-505,371
-43% -$186M 0.11% 194
2021
Q2 		$276M Buy
1,176,214
+649,446
+123% +$116M 0.12% 188
2021
Q1 		$69M Buy
526,768
+377,476
+253% +$54.7M 0.03% 463
2020
Q4 		$15.6M Buy
149,292
+45,392
+44% +$4.59M 0.01% 793
2020
Q3 		$7.35M Sell
103,900
-753,857
-88% -$52.6M ﹤0.01% 868
2020
Q2 		$55.1M Buy
857,757
+776,564
+956% +$42.5M 0.03% 461
2020
Q1 		$2.43M Buy
+81,193
New +$1.87M ﹤0.01% 978

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Janus Henderson Group's MRNA Position: Q1 2026 in Review

Janus Henderson Group increased its Moderna (MRNA) stake by 4.1% in Q1 2026, buying an estimated $296K and bringing the position to 159,372 shares worth $8.1M. The position accounts for ﹤0.01% of the portfolio, ranked #826.

Janus Henderson Group first reported a position in MRNA in Q1 2020 and has held it in 25 quarters since. The position peaked at $276M in Q2 2021. 725 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Janus Henderson Group held 159,372 shares of Moderna worth $8.1M as of Q1 2026.
  • Janus Henderson Group bought 6,337 Moderna shares in Q1 2026, an estimated $296K.
  • Moderna made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #826 holding.
  • Janus Henderson Group first reported a position in Moderna in Q1 2020 and has held it in 25 quarters since.
  • Janus Henderson Group's Moderna position peaked at $276M in Q2 2021.
  • 725 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.